Board of Directors
The Physicians Network Board of Directors is composed of nine faculty members representative of the clinical divisions at MD Anderson. Each Director is appointed by the President of MD Anderson Cancer Center and serves a three year term. A Director may serve successive terms.
The responsibilities of the Board of Directors include:
- Establish Physicians Network mission and vision statements and review them periodically to insure they fit well with the direction of the corporation
- Approve the strategic plan, which outlines strategies to grow the business of the organization, including the necessary resources
- Determine and approve the products and services to be offered that are consistent with the mission and vision
- Approve the annual operating budget and ensuring effective management of resources
- Build and maintain a strong public image by promoting the mission, vision and programs of the organization
- Recruit, train and evaluate board members and maintain a Board composition that is balanced and appropriate
- Ensure that the Physicians Network maintains ethical and legal practices to ensure accountability
- MD Anderson Physicians Network Org Chart
Frederick C. Ames, MD
Frederick C Ames, MD, FACS is Clinical Professor in the Department of Surgery. He previously was the Robert F. Fly Professor and Deputy Chairman of the Department of General Surgical Oncology retiring from full time service in 2007 after 30 years service. For the past 20 years his practice has been focused on breast disease and he previously served as Head of the Breast Surgical Section. He has authored or co-authored over 200 journal articles and book chapters the majority of which focus on breast disease. He continues to serve as Clinical Professor on the Breast Surgical Service actively treating patients.
Richard J. Babaian, M.D.
Chief Medical Officer
Richard J. Babaian, M.D., is Professor and Senior Medical Director. Prior to serving in this role, Dr. Babaian was Professor of Surgery in the Department of Urology, Director of the Prostate Detection Clinic and the Blanche Bender Professor in Cancer Research at the University of Texas MD Anderson Cancer Center.
Upon completion of his degree in medicine from Georgetown University, Dr. Babaian completed his internship at the University of Wisconsin and his residency at the University of Wisconsin and the University of North Carolina. Additionally, Dr. Babaian completed a three-year fellowship in Urologic Oncology.
Dr. Babaian practiced urologic oncology exclusively for over twenty years and has authored or co-authored more than 200 scientific publications the majority of which focus on prostate cancer and currently serves as a committee member on the NCCN Prostate Cancer Panel. He has a wide range of experience in the early detection, diagnosis, staging and management of prostate cancer and is experienced in the technique of cryosurgery and has utilized this modality in the treatment of prostate cancer both as primary therapy and as salvage following radiation therapy. His research interest focuses on prostate tumor markers and prediction models.
Miloslav Beran, M.D., Ph.D.
Miloslav Beran, M.D., Ph.D., graduated from Karolinska Institute Medical School in Stockholm, Sweden with both M.D. and Ph.D. degrees. He completed his internship and residency training at Karolinska Hospital in Stockholm and MD Anderson Cancer Center fellowship program in Developmental Therapeutics from 1978-1980. After a short time as Assistant Professor of Medicine in charge of bone marrow transplantation for the Department of Hematology, Karolinska Hospital, Dr. Beran joined the staff of MD Anderson Cancer Center as Associate Professor and subsequently Professor of Medicine in the Department of Hematology/Leukemia, where he actively pursued both laboratory and clinical research until his retirement in 2008. Throughout his entire career, his commitments included preclinical laboratory research focused on the significance of leukemia biology for patient outcome, mechanisms of resistance to antileukemic agents and testing of new antileukemic drugs.
Dr. Beran combined these endeavors with direct patient care, development of new treatment strategies for treatment of leukemias and myelodysplastic syndromes and design and coordination of clinical trials. He published and lectured extensively and for his work received national and international recognition.
He continues collaboration with the staff of the Leukemia department.
Miguel Rodriguez-Bigas, M.D.
Dr. Miguel A. Rodriguez-Bigas graduated from the University of Puerto Rico Medical School in 1982. Following a General Surgery Residency at the University Medical Center and the University of Puerto Rico affiliated hospitals, he went to Roswell Park Cancer Institute where he finished a Surgical Oncology Fellowship (1987-88, 1989-90) and a Head and Neck Oncologic Surgery Fellowship (1988-89). Dr. Rodriguez-Bigas spent 11 years in the staff at Roswell Park Cancer Institute's Department of Surgical Oncology in the Colorectal Division prior to coming to the Department of Surgical Oncology at MD Anderson Cancer Center in 2001.
Dr. Rodriguez-Bigas has published over 150 peer-reviewed articles and book chapters. Most recently he co-edited a book titled Hereditary Colorectal Cancer. He has served on the Editorial Boards of the Journal of Clinical Oncology, Diseases of the Colon & Rectum, and Annals of Surgical Oncology. Currently he is on the Editorial Board of Familial Cancer, and he is a member of the National Cancer Institute Physicians Desk Query (PDQ) Cancer Genetics Editorial Board. In addition, he has been an invited speaker in both national and international symposia dealing with colorectal cancer and inherited colorectal cancer. He is also a member of the American Cancer Society Colorectal Cancer Advisory Committee and was a member of the American College of Surgeons Commission on Cancer from 2000-2010 serving as chairperson of the Education Committee from 2006-2009.
Throughout his career, Dr. Rodriguez-Bigas has developed a special interest in the Hereditary Colorectal Cancer Syndromes. In 1996, he was the Chairperson of a National Cancer Institute Workshop titled "The Intersection of Pathology and Genetics in the Hereditary Nonpolyposis Colorectal Cancer Syndrome". It was in this workshop where the Bethesda Guidelines for testing colorectal tumors for microsatellite instability were developed. This workshop served as the basis for a second workshop in 1997 where the specific molecular markers and guidelines for defining microsatellite instability were formulated. In 2003, a third workshop was reconvened to re-evaluate the original Bethesda Guidelines as well as to examine whether any changes to the previous recommendations on clinical guidelines, molecular markers, and definitions were warranted. These criteria are widely used worldwide. Dr. Rodriguez-Bigas is currently past co-chair of the International Society for Gastrointestinal Hereditary Tumors (InSiGHT).
Peter Dempsey, MD., F.A.C.R
Before joining MD Anderson Physicians Network, Dr. Dempsey served as Professor, Diagnostic Radiology, Division of Diagnostic Imaging at MD Anderson Cancer Center. He also served as Section Head of Breast Imaging within the Breast Cancer Center. Prior to coming to MDACC Dr. Dempsey was at the University of Alabama Medical Center where he was Chief of Outpatient Radiology and Section Chief of Breast Imaging. Dr. Dempsey has published 70 peer reviewed journal articles and 5 book chapters.
Helmuth Goepfert, M.D.
Helmuth Goepfert, M.D., is Professor Emeritus and Medical Director. Prior to serving in this role, Dr. Goepfert was Department Chair of Head and Neck Surgery and Professor of Surgery. He was an administrative leader and practicing surgeon at MD Anderson Cancer Center for over thirty one years. His experience in clinical oncology and management of medical professionals is applied to his role in quality improvement process and concordance studies.
William A. Hyslop, FACHE
President and Chief Executive Officer
Mr. Hyslop has more than 30 years as a health care leader and has been with the MD Anderson Physicians Network since 1999. In his present capacity he has chief executive responsibilities for both the MD Anderson Physicians Network and the MD Anderson Services Corporation. Both corporations are subsidiary corporations to the MD Anderson Cancer Center and are involved in business relationships external to the MD Anderson Cancer Center. During Mr. Hyslop’s career, he has served as chief executive officer of three general acute care hospitals ranging in size from 250 beds to 400 beds and also as a regional CEO overseeing 7 not-for-profit community hospitals. He additionally organized and operated a national consulting firm that focused on healthcare merger and acquisitions, strategic business development and start-up company formations. He has worked in a diversity of settings that include for-profit and not-for-profit hospitals, independent hospitals and multi-hospital corporations as well as both public-general and academic organizations.
Deborah Kuban, M.D., F.A.C.R., F.A.S.T.R.O
Dr. Deborah Kuban is Professor of Radiation Oncology, Genitourinary Section Chief, Medical Director of the Multidisciplinary Prostate Cancer Clinic, and Director of Radiation Oncology Global Development at the University of Texas M.D. Anderson Cancer Center in Houston, Texas. A graduate of the Medical College of Georgia, Dr. Kuban completed an internship in Surgery and a residency in Radiation Oncology at the Eastern Virginia Medical School in Norfolk, Virginia.
Dr. Kuban’s research interests include radiation for prostate cancer, quality of life after treatment, novel agents combined with radiation and the multidisciplinary approach. Dr. Kuban has authored over 300 articles, editorials, and abstracts, as well as several book chapters. She serves on the editorial boards of the International Journal of Radiation Oncology Biology Physics and Brachytherapy and is a reviewer for a variety of journals, including Cancer, Urology, and the Journal of Clinical Oncology. She is a member of the Prostate Cancer Task Force of the NCI and a fellow of the American College of Radiology and the American Society of Radiation Oncology.
Peter McLaughlin, M.D.
Prior to joining the MD Anderson Physicians Network in 2010, Peter McLaughlin, MD, had been Professor of Medicine in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center. Dr. McLaughlin received his undergraduate degree from Harvard University College, and his MD from Tufts University School of Medicine.
Dr. McLaughlin's research focus was on the integration of new therapies, particularly biological therapies, for the management of patients with indolent lymphoma. He has authored and co-authored over 200 journal articles and book chapters. He was the lead investigator of the multicenter pivotal trial of rituximab that led to its approval by the FDA in 1997. His collaborative activities ranged from inter-departmental projects at MDACC to international ones such as the development of the Follicular Lymphoma International Prognostic Index (FLIPI).
In addition to his patient care and clinical research roles, Dr. McLaughlin also participated in departmental and institutional initiatives related to medical records (including MDACC's transition to an electronic medical record), database development and maintenance, and quality improvement.
William J. Simeone, Jr., M.H.A.
Vice President, Operations
Mr. Simeone has over twenty-five years experience as a healthcare leader at MD Anderson Cancer Center and has led Operations for MD Anderson Physicians Network since 2004.
In his role as Associate Vice President, he has responsibility for all MD Anderson Physicians Network clinical operations, which include account management, case management, credentialing, information systems, member services, provider relations, program development and quality improvement. Management oversight of these functions includes all processes related to support the Cancer Manager Host Affiliates, Employer and Clinical Support Services Agreements.
David G. Tubergen, M.D.
David G. Tubergen, M.D., participates in program development and is responsible for the presentation of the Host program to the medical staff of potential participant institutions. This involves explaining the Host program content through direct interaction with the medical staff and its leadership and assessing the level of support and enthusiasm for the program. He participates in the review of the clinical due diligence process to ensure that the potential host has appropriate infrastructure, policies and procedures in place prior to beginning the Host relationship.
Vice President, Strategy and Business Development
Melanie Wong is Vice President of Strategy and Business Development for MD Anderson Physicians Network (Physicians Network). Physicians Network is a supporting company of MD Anderson Cancer Center created to support the mission of cancer prevention, treatment, research and education. In this capacity, Ms. Wong develops business strategy around the Physicians Network products and services and implements the strategies in the U.S. national market place. Ms. Wong earned a BBA in Accounting at the University of Texas at Austin.
Prior to joining Physicians Network, Ms. Wong held leadership positions in top tier healthcare organizations including, MD Anderson Cancer Center, University of Texas Health Science Center, City of Hope National Medical Center and Baylor College of Medicine. In these roles, she led strategic initiatives that included long and short range strategic planning and implementation; operations and financial turnaround initiatives; physician recruitment, retention and compensation; affiliations and mergers; and operations excellence planning.
Prior to joining Physicians Network, Ms. Wong was Senior Vice President and Managing Director of the national office of FKP Advisors which is a healthcare strategic planning and operations consulting practice. Using LEAN Six Sigma methodologies, simulation modeling and other proprietary tools, the consulting practice had unprecedented growth by expanding service line offerings and streamlining delivery methods.